Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Inflammation01:38

Inflammation

Overview
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Asymmetric Lipid Bilayer01:35

Asymmetric Lipid Bilayer

Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deletion of exon 2 in ALS-linked <i>Sptlc1</i> causes lethality in homozygous mice but not in heterozygotes.

Life science alliance·2026
Same author

BET-induced metabolic reprogramming fuels inflammation at the vascular-fat interface in mice and patients with cardiometabolic disease.

Cell reports·2026
Same author

Redirection of sphingolipid metabolism drives cytoskeletal defects in SPLIS and reveals ROCK inhibition as therapy.

The Journal of clinical investigation·2026
Same author

Sphingosine-1-phosphate - sphinganine-1-phosphate Imbalance Drives Airway Hyperreactivity.

medRxiv : the preprint server for health sciences·2026
Same author

Blood 1-Deoxysphingolipid Levels Are Associated With Epidermal Denervation in Small Fiber Neuropathy.

Journal of the peripheral nervous system : JPNS·2025
Same author

Very long-chain fatty acids drive 1-deoxySphingolipid toxicity.

Nature communications·2025

Related Experiment Video

Updated: May 17, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Sphingolipids and atherosclerosis.

Thorsten Hornemann1, Tilla S Worgall

  • 1Inst. for Clinical Chemistry, University Hospital Zuerich, Raemistrasse 100, 8091 Zuerich, Switzerland. thorsten.hornemann@usz.ch

Atherosclerosis
|October 19, 2012
PubMed
Summary
This summary is machine-generated.

Sphingolipids play a key role in atherosclerosis. Recent studies reveal how these lipids influence the development of atherosclerotic lesions, advancing our understanding of cardiovascular disease mechanisms.

Related Experiment Videos

Last Updated: May 17, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Area of Science:

  • Lipid metabolism
  • Cardiovascular disease research
  • Molecular mechanisms of atherosclerosis

Background:

  • Atherosclerotic lesions accumulate significant amounts of sphingolipids.
  • Sphingolipids are diverse lipids with crucial biological functions beyond membrane structure.
  • Advances in gene identification and mass spectrometry have enabled sphingolipid research.

Purpose of the Study:

  • To discuss recent mechanistic insights into the role of sphingolipids in atherogenesis.
  • To enhance understanding of how sphingolipids affect the atherosclerotic process.
  • To review findings from animal and epidemiological studies.

Main Methods:

  • Review of recent mechanistic insights.
  • Analysis of data from animal studies.
  • Examination of epidemiological study findings.

Main Results:

  • Identification of genes regulating sphingolipid metabolism.
  • Increased availability of mass spectrometry techniques.
  • Enhanced understanding of sphingolipid roles in atherosclerosis.

Conclusions:

  • Sphingolipids are critical regulators in the atherosclerotic process.
  • Mechanistic insights from recent studies significantly advance the field.
  • Further research is warranted to fully elucidate sphingolipid functions in cardiovascular disease.